Ranbaxy's generic Lipitor buoys Daiichi Sankyo against olmesartan weakness
This article was originally published in Scrip
Daiichi Sankyo's branded-plus-generics "hybrid" business model finally appears to be paying concrete dividends, with Ranbaxy's surging sales of generic atorvastatin offsetting global weakness for the group's top branded product Benicar/Olmetec (olmesartan) in the first quarter.
You may also be interested in...
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.